U nderstanding strategies to prevent the transmission of and reduce susceptibility to HIV-1 infection is paramount in controlling the pandemic. Some insights have emerged from epidemiological and population-based studies. For example, the probability of acquiring HIV-1 infection depends on the route and nature of exposure as well as the size of the viral inoculum, which relates to the viral load of the source partner (1) . In addition, the inheritance of certain HIV-1 coreceptor polymorphisms and HLA alleles is associated with a more favorable course of HIV-1 disease and in some instances with a reduced susceptibility to infection (2) (3) (4) (5) (6) . However, there is no evidence as yet that natural immunity to HIV-1 infection exists and can protect against infection. If such immunity could be identified, the findings would have major relevance to vaccine development.
Steps toward understanding potential mechanisms of natural immunity have focused on observational studies of persons who resist infection despite repeated viral exposure. The most remarkable findings have emerged from a group of highly exposed commercial sex workers (CSW) 3 in Nairobi who have remained free of infection for at least 3 and up to 12 years (7) (8) (9) . Over time, we and others have described additional cohorts with similar apparent abilities to resist infection. The presence of HIV-1-specific cellular immunity (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) and in some cases humoral immunity (18 -27) has been demonstrated in these individuals, and it was not linked to the inheritance of protective HIV-1 coreceptor mutations. To date, the most consistent finding in exposed seronegative (ES) cohorts has been the presence of HIV-1-specific CD8 ϩ CTLs, detected by either cytolytic activities or secretion of antiviral mediators such as IFN-␥.
Studies in HIV-1-infected individuals have demonstrated that HIV-1-specific CTL are critical for the control of viremia (28 -33) , making the possibility that CTL assume a similar role in protecting ES individuals against overt HIV-1 infection an attractive hypothesis. However, linking CTL to protective immunity in ES individuals has been difficult. Frequencies of HIV-1-specific CTL are generally lower in ES than in HIV-1-infected individuals, and often the responses are intermittent and/or not persistent (7, 34) . Although HIV-1-specific CD8 ϩ T cell lines and CD4 ϩ T cell clones from ES blood have been demonstrated by two groups in 1995 and 1997, respectively (15, 35 ), this has not been possible in most cases, which has created skepticism about their very existence. In addition, there has been no direct demonstration that CTL decline before certain ES fail to remain protected and seroconvert (8) .
Most CTL studies in ES individuals have been conducted in female CSW in Africa (7-9, 11, 12) or heterosexual couples discordant for HIV-1 infection (14, 20) . Since the per-contact probability of HIV-1 transmission through the genital mucosa is only ϳ0.001 (1), a distinction between heterosexual ES who remain uninfected on the basis of protective CTL or chance alone requires very large cohorts and/or extremely high exposure rates. In contrast, the per-contact infectivity of anal intercourse is ϳ1 log higher (1) , and men having sex with men (MSM) who frequently practice unprotected sex with HIV-1-infected partners are potentially more suitable to address the role of HIV-1-specific CTL in protection.
To understand the factors contributing to the induction and persistence of CTL in ES, we initiated a study to first define the quantity, fine specificities, and breadth of CD8 ϩ CTL and CD4
ϩ Th cell responses in a well-characterized cohort of MSM followed longitudinally up to 6 years in Seattle, WA. The 46 MSM reported frequent unprotected anal sex with known HIV-1-infected partners. We initially employed a standard IFN-␥ ELISPOT assay to assess responses to HIV-1 Env, Gag, Pol, and Nef epitopes. This procedure had undergone vigorous quality control analysis and validation for implementation into phase I and II vaccine trials (36) . To amplify responses in cases of low precursor frequencies just below the level of detection, we also analyzed selected very high risk individuals by optimized ELISPOT and intracellular IFN-␥ flow cytometric protocols using autologous dendritic cells (DCs) for Ag presentation. Despite continued and frequent high risk behavior, we observed minimal to absent frequencies of IFN-␥-secreting, HIV-1-specific T cells in the majority of individuals tested, even with DC stimulation. Clearly positive responses were present in only three individuals, one of whom seroconverted 6 mo after ELISPOT testing. Our findings suggest that in the majority of our highly exposed cohort neither CD8 ϩ CTL nor CD4 ϩ Th cells were critical for protection against HIV-1 infection.
Materials and Methods

Study population
Healthy HIV-1 seronegative men, Ն18 years old, who reported high risk sexual activity with known HIV-1-infected men were recruited within metropolitan Seattle for longitudinal study at the Fred Hutchinson Cancer Research Center HIV-1 Vaccine Trials Unit. Enrollment criteria were unprotected anal receptive and/or insertive intercourse with a known HIV-1-infected man six times or more in the previous 6 mo or an average of twice weekly for Ն4 mo within 2 years of enrollment. Prior receipt of an HIV-1 vaccine was an exclusion criterion. Volunteers entering the study were designated ES. A medical history, physical examination, complete blood cell count, T cell subset analysis, and HIV-1 testing were performed at the screening visit to confirm eligibility. HIV-1 infection was excluded by the following tests performed at the screening visit and on study day 0: HIV-1/2 ELISA and Western blot (37), HIV-1 plasma RNA RT-PCR (Amplicor HIV-1 Monitor; Roche, Branchburg, NJ) (38) , and PBMC DNA PCR (39) . HIV-1/2 ELISA and Western blot were repeated every 3 mo. HIV-1 PBMC DNA PCR was performed again 4 and 8 wk after enrollment and then repeated yearly. Clinicians performed HIV-1 risk reduction counseling during each visit. The volunteers completed a questionnaire concerning risk behavior and provided blood during visits scheduled every month over the initial 3 mo and every 3-6 mo thereafter.
A control group of 13 HIV-1-seronegative, monogamous, and sexually active individuals, Ն18 years of age, were also recruited for comparison of T cell responses to HIV-1. These subjects, designated ES controls, were all Caucasian and consisted of nine homosexual men, one heterosexual man, and three heterosexual women. They reported at least one episode of unprotected intercourse with an HIV-1-seronegative partner in the 6 mo before screening and no previous history of HIV-1 exposure. In addition, the HIV-1-infected partners of the ES were recruited as previously described (10) . They all tested positive by HIV-1 ELISA and Western blot and thus provided confirmation of high risk exposure.
Each volunteer provided written consent before enrollment. All aspects of the study were approved by the institutional review board at the University of Washington and the Fred Hutchinson Cancer Research Center.
CCR5 genotype analysis
To determine whether volunteers inherited the 32-bp deletion within the trans-membrane region of CCR5, DNA was isolated from PBMC and amplified by PCR with primers and conditions previously described (2, 3) . The amplicons were subjected to agarose gel electrophoresis, and the size was assessed for the absence or the presence of a 32-bp deletion as previously described (10) .
IFN-␥ ELISPOT assay
To evaluate T cell responses recognizing HIV-1 epitopes, IFN-␥ ELISPOT assays were performed either on whole PBMC or selected T cell subsets. For the latter, PBMC were reacted with anti-CD8 magnetic microbeads (Miltenyi Biotec, Auburn, CA) and sorted into CD8 ϩ and CD8 Ϫ cells on a paramagnetic separation column according to the manufacturer's instructions. On the average, 70 -90% of PBMC were recovered after magnetic bead selection, the ratio of the purified CD8 ϩ and CD8 Ϫ fractions was ϳ1:2.3, and purity of the CD8 ϩ T cell fraction was Ͼ95%. Synthetic 20-mer peptides overlapping by 10 aa and synthetic 15-mer peptides overlapping by 11 aa, each set spanning the entire HIV-1 subtype B (HXB2) Gag, Env, Pol, and Nef region, were obtained through the National Institutes of Health AIDS Research and Reference Program (Bethesda, MD). Optimal 8-and 9-mer peptides with known HLA class I restriction patterns were synthesized by either Chiron (Emeryville, CA) or the Proteomics Facility of the Fred Hutchinson Cancer Research Center. The peptides were reconstituted at a concentration of 2 mg/ml in 100% DMSO (Sigma-Aldrich, St. Louis, MO) and were used at a final concentration of 2 g/ml. A pool of five irrelevant peptides derived from actin and a highly conserved region of HLA class I ␣-chain precursor were used as negative controls (Mimotopes, Clayton, Australia).
Cryopreserved PBMCs were thawed, allowed to rest in complete medium overnight at 37°C in 5% CO 2 , and plated in 96-well, hydrophobic, polyvinylidene difluoride-backed plates (Millipore, Bedford, MA) previously coated with 50 l of 10 g/ml anti-IFN-␥ mAb (clone 1-D1K; Mabtech, Nacka, Sweden) overnight at 4°C. The cells were added to the wells in either duplicate or triplicate at 2 ϫ 10 5 cells/well in 100 l of complete medium. HIV-1-specific peptides and negative control peptides were added to the wells at a final concentration of 2 g/ml. Cells stimulated with PHA (1 g/ml; Sigma-Aldrich), staphylococcal enterotoxin B (SEB; 1 g/ml; Sigma-Aldrich), or an immunodominant HLA-A2-restricted CMV p65 9-mer peptide (NLVPMVATV, 2 g/ml; Mimotopes) served as positive controls. Plates were incubated overnight (16 -20 h ) at 37°C in 5% CO 2 , washed with PBS containing 0.05% Tween 20, and incubated at room temperature for 2 h with biotinylated anti-IFN-␥ mAb at 1 g/ml (7-B6-1; Mabtech). The avidin-biotinylated enzyme complex from the Vectastain ABC Elite Kit (PK-6100; Vector Laboratories, Burlingame, CA) was added at room temperature for 1 h, followed by the Vectastain 3-amino-9-ethyl-carbazole peroxidase substrate. Spot-forming cells (SFC) were counted using an automated ELISPOT reader (Immunospot; Cellular Technology, Cleveland, OH).
Use of DCs as APCs in the IFN-␥ ELISPOT assay
To generate autologous DCs in vitro, PBMCs were enriched for DC precursors and monocytes by plastic adherence for 90 min at 37°C in 5% CO 2 (40) . The nonadherent fraction was discarded, and the adherent cells were cultured for 8 days with 800 U/ml GM-CSF and 800 U/ml IL-4 (PeproTech, Rocky Hill, NJ) in RPMI 1640 supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 1 mM HEPES (BioWhittaker, Walkersville, MD), and 10% heat-inactivated FBS (Gemini, Calabasas, CA; complete medium). The cytokines were added to the cultures on days 0, 3 and 6. On day 6, cultures were supplemented with monocyte-conditioned medium (MCM) at 25% (v/v) to induce maturation (41) . Mature DCs were collected on day 8.
The DC-ELISPOT was conducted similarly to the standard overnight ELISPOT assay with the following changes: 10 4 mature DCs/well were first added in duplicate or triplicate to the anti-IFN-␥ mAb-coated, 96-well, hydrophobic, polyvinylidene difluoride-backed plates in 50 l of complete medium. The DCs were pulsed with the HIV-1-specific 15-mer and negative control peptides at a final concentration of 4 g/ml for 1 h at 37°C in 5% CO 2 . CD8-enriched and CD8-depleted PBMC fractions were then added in 50 l of complete medium at a final concentration of 10 5 cells/ well for overnight incubation and subsequent IFN-␥ detection.
Statistics and criteria for a positive HIV-1-specific ELISPOT assay
Absolute SFCs are reported per 10 5 mononuclear cells and after subtraction of background IFN-␥ secretion in the cultures containing the control peptides. Criteria for a positive culture are based on a likelihood ratio statistic assuming the numbers of SFCs per well approximate a simple Poisson distribution (36, 42) . 4 This allows conversion of data into a binomial distribution by calculating, for each peptide pool tested, the proportion of total SFCs attributable to the experimental wells (with the total SFCs being the sum of all SFCs in the experimental and control wells). We then applied an exact one-sided test to determine the likelihood that this proportion is significantly greater than would be expected if the SFCs were randomly distributed across the experimental and control wells. Results with a likelihood of ␣ Յ 0.01 of having occurred merely by chance were considered positive. Since multiple peptide pools were tested per assay in each individual, this ␣ level was adjusted for multiple comparisons by the Bonferroni correction. Differences between the ES and the control cohort were tested for statistical significance using Fisher's exact test. With 15 subjects in the ES and 13 subjects in the control cohort, a difference of 50% in the proportion of responders between the two groups can be detected by a one-sided test with ␣ Յ 0.05 and a power of Ͼ80%.
Detection of intracellular IFN-␥ production by flow cytometry
Staining for intracellular IFN-␥ was performed as described by Bitmansour et al. (43) . In brief, thawed PBMCs were stimulated with anti-CD28 mAb (L293; BD Biosciences, San Diego, CA) and anti-CD49d at 5% CO 2 in 37°C (HP2/1; Coulter, Miami, FL; both 1 g/ml final concentration), followed by the HIV-1-specific 15-mer, the negative control peptide, or SEB as the positive control. After incubation for 1.5 h, brefeldin A (10 g/ml; BD Biosciences) was added for an additional 5 h. Cells were then washed and stained with fluorochrome-conjugated mAbs for surface markers (anti-CD4-PE, RPA-T4; anti-CD8-PE-Cy5, HIT8a; anti-CD3-allophycocyanin, SK7) and intracellular IFN-␥ (anti-IFN-␥-FITC, 25723.11; all from BD Biosciences) according to the manufacturer's protocol. In some experiments a combination of anti-IFN-␥-FITC, ethidium monoazide bromide (EMA; Molecular Probes, Eugene, OR), anti-CD14-PE (RMO52; Coulter), anti-DC-SIGN-PE (120507; R&D Systems, Minneapolis, MN), anti-CD4-PE-Cy5 (RPA-T4), and anti-CD8-allophycocyanin (RPA-T8; both from BD Biosciences) was used to exclude EMA ϩ dead cells, CD14 ϩ monocytes, and DC-SIGN ϩ DCs, all falling in the FL2 channel, from the analysis. Cells were fixed in 0.5% paraformaldehyde (JT Baker, Phillipsburg, NJ), and analyzed on a Calibur flow cytometer (BD Biosciences) for fourcolor fluorescence. Cells incubated with the negative control peptide pool and/or stained with matching isotype control mAbs (BD Biosciences) were used to define background staining and quadrant markers. Cells stained with only one specific mAb were used to compensate for overlapping signals between different fluorescence channels. 
Results
Study population
The ES study population consisted of 46 MSM with an identified HIV-1-infected sexual partner who met the enrollment criteria and had no evidence of HIV-1 infection by serology and routine PCR testing. Forty-four (92%) reported unprotected anal intercourse six times or more during the 6 mo before enrollment, and two (4%) engaged in these activities a minimum of twice weekly for Ն4 mo within the past 2 years. Seven of the 46 MSM also acknowledged i.v. drug use. The median age at study entry was 38 years (range, 24 -60) . The majority (96%) of the study participants were Caucasian; two ES were Hispanic. Two ES individuals were homozygous (ES7 and ES61), and 12 were heterozygous for the CCR5⌬32 mutation, which were higher, but not statistically different, frequencies than those reported for the general population (3).
The ES MSM were followed for a median of 280 wk (range, 30 -340 wk) or 5.4 years. The majority continued to report unprotected anal intercourse with known HIV-1-infected partners (70% during the first 6 mo after recruitment), although this activity tended to decline over time (Table I and Fig. 1 ). At present, 18 of 39 ES individuals (46%) who were followed for Ն1 year still practice unprotected anal intercourse with known HIV-1-infected partners. At the same time, high risk sexual activity with partners of unknown HIV-1 status increased nearly 2-fold, from 13 of 46 (28%) ES individuals practicing unprotected anal sex during the first 6 mo after recruitment to 20 of 39 ES individuals (51%) at present ( Table I ). The total number of sexual partners also increased during the study period (Table I ). The number of individuals reporting five or more different partners per 6-mo period nearly doubled from 14 during the first 6 mo of the study to 22 at present. At the most recent visit, only 13 ES reported sex exclusively with the same HIV-1-infected partner as at the time of enrollment.
Six of the 46 ES seroconverted during the observation period ( Fig. 1 ), corresponding to a seroincidence rate of 4.02 HIV-1 infections/100 person years (95% confidence interval, 1.6, 8.14). In comparison, the seroincidence rate for MSM who reported unprotected intercourse with HIV-1-infected partners and were enrolled for the contemporaneous Seattle HIVNET Vaccine Preparedness Study (employing less stringent risk criteria than for our ES MSM cohort) was 7.68 (95% confidence interval, 4.13,14.27) (44). Of note, two of the seroconverters (ES28 and ES62) reported no high risk activities with known HIV-1-infected partners between study entry and the date of seroconversion (Fig. 1) . Taken together, these findings indicate that markedly high risk activities persisted in at least one-half of the ES MSM with their known HIV-1-infected partner and increased in the majority with partners of unknown HIV serostatus.
HIV-1-specific T cell responses by standard IFN-␥ ELISPOT assay
To determine whether HIV-1-specific, IFN-␥-secreting T cells are present in the peripheral blood of the ES MSM, we tested PBMC from 26 ES individuals at one visit (n ϭ 19) or two or more visits (n ϭ 6) using an overnight ELISPOT assay. These analyses were focused on fresh specimens and cryopreserved PBMC from known CTL responders and nonresponders (10) . The expression of HIV-1 epitopes was accomplished by pulsing PBMC with pools containing 10 20-mer peptides overlapping by 10 aa and spanning the complete HIV-1 Env, Gag, Pol, and Nef region. This assay and the statistical criteria used to determine positive HIV-1-specific responses were validated in previous experiments. In comparisons between uninfected unvaccinated controls and either HIV-1-seropositive individuals (36) or recipients of a recombinant canarypox ALVAC-HIV vaccine (vCP 1452) in a large phase II vaccine trial (H. Horton et al., manuscript in preparation), the test approached a specificity of 100%. As shown in Fig. 2 , this assessment allows robust discrimination of positive responses based on a constant probability of false positive responses Յ0.01 regardless of varying numbers of IFN-␥ SFCs in the negative control wells. Only four of the 26 ES (15%) tested positive to one (n ϭ 3) or more peptide pools (n ϭ 1) using the criteria established (Fig. 2) . PBMC from ES40 recognized the Gag 1-10 and the Env 51-60 pool at one visit and the Pol 91-100 and the Nef 11-20 pool at a later visit. These responses ranged from 7-17.7 IFN-␥ SFCs/10 5 PBMC. At a third visit, all peptide pools tested negative. PBMC from ES48 recognized the Pol 31-40 pool (6.6 SFCs) at one visit and tested negative at two additional visits. ES58 PBMC recognized the Env 21-30 pool (7.7 SFCs), and ES60 PBMC recognized the Pol 81-90 pool (9.3 SFCs) at the single visit tested for each individual. Thus, examination of ex vivo IFN-␥-secreting T cells recognizing four HIV-1 gene products reveals a low frequency of responders among our ES MSM individuals and a low level of responses when positive.
Amplification of HIV-1-specific IFN-␥ production following Ag presentation by autologous DCs
The low frequency of HIV-1-specific, IFN-␥ secreting T cells in this highly exposed cohort suggested that HIV-1-specific CTL were mostly absent or their detection required more sensitive techniques. Thus, we considered alternative approaches to identify these responses if present. Since DCs are extremely efficient at Ag presentation and activation of T cells, the use of DCs to present the HIV-1 peptides could potentially reveal low level HIV-1-specific responses (45) (46) (47) (48) . We therefore established an ELISPOT protocol that employed autologous DCs for peptide presentation (DC-ELISPOT). The assay conditions were delineated first in six chronically HIV-1-infected individuals and then employed in the ES and control groups.
Initial studies determined the specific number of days of DC differentiation and maturation to achieve optimal stimulation. Amplification of responses was observed at all three time points of DC maturation tested. However, the best overall enhancement of HIV-1-specific responses compared with stimulation in the absence of autologous DCs was achieved when DCs were used on day 8 of in vitro differentiation and after 2 days of maturation with MCM (Fig.  3a, representative donor) . Under these conditions, autologous DCs mixed with PBMC at a ratio of 1:10 amplified responses to either HIV-1 peptide pools or single peptides an average of 3.2-fold (range, 1.69 -7).
We then examined HIV-1-specific T cell responses using the DC-ELISPOT assay in six patients, five of whom were long term nonprogressors (LTNP). We employed selected peptides or peptide pools in these assays and compared responses with those to the control peptides. As shown in Fig. 3b , IFN-␥-secreting T cells were readily detected in the six HIV-1-infected patients with SFC frequencies ranging from 16 -296/10 5 PBMC. By contrast, the SFC were Ͻ10/10 5 PBMC when stimulated with the control peptides. These frequencies were similar to or greater than those previously noted for cells from these patients obtained at the same or different time points using the standard IFN-␥ ELISPOT assay (data not shown).
Finally, we determined the ability of mature autologous DCs to trigger HIV-1-specific T cells to produce IFN-␥ in ES40. As previously shown, ES40 exhibited low level responses in two of three visits by the standard ELISPOT assay (Fig. 2) , and the DC-ELISPOT studies were performed with PBMC from an additional visit. Peptide presentation by autologous DCs sufficiently enhanced the sensitivity of detection to uncover low frequency, IFN-␥-secreting memory T cells responsive to the HIV-1 Env 1-10 and Env 21-30 20-mer peptide pools, which would have been missed by standard ELISPOT assay (Fig. 3c) . Responses to the other three HIV-1 peptide pools tested remained negative by our criteria. In addition, the responses to the irrelevant control peptides were similar for cultures with or without DCs and were Ͻ5 IFN-␥ SFCs/10 5 PBMC. These results indicate that peptide presentation by mature autologous DCs is a suitable method to reveal low frequencies of circulating HIV-1-specific, IFN-␥-secreting memory T cells in ES, and thus we proceeded to evaluate the ES and the ES controls using this approach.
Frequency and magnitude of HIV-1-specific responses in ES and ES controls tested by DC-enhanced ELISPOT assay
To improve the distinction between true false positive responses due to recognition of non-HIV-1 cross-reactive epitopes and genuine responses to HIV-1 epitopes, we conducted the DC-ELISPOT in 13 HIV-1-uninfected adults who were monogamous with a known HIV-1-uninfected partner along with the studies in the ES. In addition to using DCs as APCs, we further increased the sensitivity for detection of HIV-1-specific T cells by employing peptides that were 15 aa in length (overlapping by 11 aa) instead of the 20-mers (36) . Five of 13 controls exhibited reactivity to HIV-1 peptide pools, and the IFN-␥-secreting responses were mediated by both CD8 ϩ (n ϭ 3) and CD8 Ϫ (n ϭ 4) subsets (Figs. 4 and 5 ). The most striking responses were observed in one MSM (C1001; Fig. 4a ), whose CD8 ϩ T cells recognized epitopes within six peptide pools (median of 29 IFN-␥ SFCs/10 5 cells; range, 12-89) and whose CD4 ϩ T cells recognized three pools (median of 10 IFN-␥ SFCs/10 5 cells; range, 9 -11). Of the other four responders in the control group (Fig. 4a) , three were MSM, and one was a heterosexual man. Responses in these four ES controls were directed against three or more peptide pools, and the mean SFC counts per peptide pool were low, ranging from 6 -12/10 5 CD8 ϩ cells and from 27-138/10 5 CD8 Ϫ cells. To optimize the probability of detecting an HIV-1-specific T cell response, we selected 15 ES based on their persistent high risk behavior and the availability of frozen PBMC. These ES are indicated in bold in Fig. 1 , and the visit from which the specimen was assayed is designated by a black triangle. Eight of the 15 ES demonstrated HIV-1-specific, IFN-␥-producing T cells, and both CD8 ϩ (n ϭ 6) and CD8 Ϫ (n ϭ 5) responses were found (Fig. 4,  b and c, and Fig. 5 ). Of the eight responders, PBMC from four exhibited a level of response similar to that in the ES controls, as shown in Fig. 5 . Two of these individuals demonstrated T cell responses to only one peptide pool (Pol The overall proportions of responders in the control cohort (38%) and the ES cohort (53%) were not statistically different ( p ϭ 0.48). Likewise, no statistically significant difference was observed when the proportions of responders were analyzed in the CD8 ϩ ( p ϭ 0.68) and the CD8 Ϫ ( p ϭ 1.0) subsets. Thus, the majority of ES MSM in our cohort had minimal to absent HIV-1-specific IFN-␥ ELISPOT responses, even when the sensitivity of the assay was optimized by presentation of peptides with autologous DCs. Only two individuals, who remained uninfected despite documented long term, high risk behavior, demonstrated responses to HIV-1 peptide pools whose breadth and magnitude clearly exceeded that observed in either the control cohort or the remaining uninfected ES MSM.
Risk behavior and HIV-1-specific T cell responses over time
Examination of HIV-1-specific, IFN-␥-secreting T cells at a single visit could not reliably distinguish between the presence of a true HIV-1-specific memory T cell population in the ES group and nonspecific or cross-reactive responses in the control group, even when DCs were used for peptide presentation. Since risk behavior in the ES cohort changed over the course of study, as exemplified in Fig. 6a for ES15, we reasoned that repeated priming of HIV-1-specific T cells during phases of increased high risk activities may boost HIV-1-specific immunity. If such boosts were observed at additional visits and in correlation with intensified risk behavior, this would signify the presence of true HIV-1-specific T cell memory. We first analyzed three of the low responders, ES1, ES40, and ES43, at three additional visits that occurred during or shortly after a period of high risk activities for reactivity to the HIV-1 peptide pools previously recognized in the DC-ELISPOT assay. (These visits are depicted by gray triangles in Fig. 1 ). To clearly distinguish between CD4 ϩ and CD8 ϩ T cell responses, we chose intracellular IFN-␥ detection and simultaneous CD4, CD8, and CD3 surface phenotyping by flow cytometry for this longitudinal analysis.
All three individuals had detectable responses by intracellular IFN-␥ staining when the peptide pools were presented by autologous dendritic cells, and the distribution of positive responses between the CD4 ϩ and CD8 ϩ T cell subpopulations was concordant with the findings by DC-ELISPOT. However, responses were low (mean of 103 IFN-␥-secreting T cells/10 5 T cells; range, 40 -150), sporadic, and directed at one to three peptide pools per visit only (data not shown). In ES1, CD8
ϩ , but not CD4 ϩ , T cells reacted exclusively to the Pol 201-225 peptide pool at all three visits. In ES40, CD4
ϩ , but not CD8 ϩ , T cells reacted exclusively to the Pol 201-225 peptide pool at two of three visits. T cells from ES40 were also tested by another DC-ELISPOT assay at a fifth visit, and no HIV-1-specific responses were noted. In ES43, CD4
ϩ T cells reacted to the Pol 101-125 and the Nef , and CD8 ϩ T cells reacted to the Nef 26 -49 peptide pool at one visit only. Thus, despite focusing examination during periods of documented high risk behavior, HIV-1-specific T cell responses in ES1, ES40, and ES43 never reached the breadth, magnitude, and/or longitudinal consistency that persuasively confirmed the presence of true HIV-1-specific immunological memory.
In contrast to the paucity of responses detected at one or more visits in the majority of ES individuals, the high frequencies of HIV-1-specific, IFN-␥-producing T cells in ES15, ES29, and ES63 may indicate true HIV-1-specific immunity, and we sought to confirm this by longitudinal analysis. We therefore tested ES15, who regularly practiced unprotected anal intercourse with known HIV-1-infected partners over the whole study period of 72 mo (Fig. 6a) , at eight additional visits by intracellular IFN-␥ staining (Fig. 6, b  and c) . In initial experiments the frequencies of HIV-specific, IFN-␥-producing T cells detected by flow cytometric intracellular staining were surprisingly high, but were accompanied by relatively high background levels (data not shown). Thus, we could not reliably distinguish between specific and unspecific binding of the FITC-conjugated anti-IFN-␥ Ab. However, when dead cells, monocytes, and added DCs were strictly excluded from the analysis (see Materials and Methods), background IFN-␥ staining of cells treated with the irrelevant peptide pool and background isotype staining were greatly reduced. We therefore repeated all time points with this approach, using the three peptide pools that stimulated the highest frequencies of IFN-␥-producing T cells in our initial studies. Only Env 151-175 was recognized at more than one time point (32, 38 , and 65 mo) and by both CD4 ϩ and CD8 ϩ T cells (Fig. 6, b and c) . The Env 126 -150 and Pol 101-125 peptide pools were recognized exclusively by CD8
ϩ T cells at one visit each (9 and 32 mo, respectively). Overall, frequencies were mostly low (mean, 77 IFN-␥ ϩ T cells/10 5 T cells; range, 20 -220), and four visits tested entirely negative.
Autologous DCs were used for Ag presentation in all of these intracellular IFN-␥-staining experiments, except at 69 mo. However, we performed another DC-ELISPOT assay at this visit, testing not only the Pol and Env peptide pools, but also 15-mer peptides spanning the complete regulatory gene regions of HIV-1 and 11 8-or 9-mer peptides restricted to HLA haplotypes found in ES15. Of this comprehensive spectrum of HIV-1 peptides, PBMC from 69 mo were reactive only to the Env 151-175 pool (219 IFN-␥ SFCs/10 5 PBMC; data not shown). Of note, ES15 had also been tested initially by our standard ELISPOT assay (44 mo), and no responses were found in the absence of DCs. Taken together, in our longitudinal analysis, we could not corroborate the broad and strong DC-ELISPOT reactivity found at 44 mo. Rather, responses were infrequent and weak, comparable to those in ES1, ES40, and ES43, and a correlation to risk activity could thus not be established.
In ES29, the other strong responder in our initial DC-ELISPOT assay who has remained uninfected to date, only two additional time points were available for analysis. One time point tested entirely negative by DC-ELISPOT, and at the other visit PBMC of ES29 reacted only to the Env 151-175 peptide pool (23 IFN-␥ SFCs/ 10 5 PBMC; data not shown). Of note, no responses were observed to 11 optimal 9-mer peptides with known restriction to HLA haplotypes present in ES29 and to the peptide pools representing the regulatory HIV-1 genes. Thus, as in ES15, we could not substantiate the reactivity found in our initial DC-ELISPOT assay at two further time points. In sum, even if rare individuals such as ES15 and ES29 sporadically exhibited increased frequencies of HIV-1-specific, IFN-␥-producing T cells, responses over time were mostly weak or absent.
Epitope mapping and T cell cloning
To confirm the presence of and further define HIV-1-specific T cells in ES15 and ES29, we repeatedly attempted to map T cell reactivities to single HIV-1 epitopes and to establish HIV-1-specific T cell clones in these individuals. In ES15, single epitope reactivities were not discernible, and HIV-1-specific T cell lines or clones did not grow out in vitro. In ES29, T cells reactive to one FIGURE 5. HLA class I serotypes, CCR5 genotypes, and frequencies of HIV-1-specific, IFN-␥-secreting CD8 ϩ and CD8 Ϫ T cells in eight of 15 ES and five of 13 control individuals reactive by DC-ELISPOT assay. Selection of CD8 ϩ and CD8 Ϫ T cells, generation and peptide pulsing of mature DCs, and ELISPOT assays were performed as described in Materials and Methods. If more than two peptide pools were recognized within a gene region, the number of recognized pools is indicated.
was performed as described in Materials and Methods. The plot design is identical with that in Fig. 2 . The black jagged line is the cutoff between negative and positive results based on a set false positive rate of ␣ Յ 0.01 and 26 different peptide pools tested. The gray jagged line is based on five different peptide pools tested and applies to ES40 only. The cutoff was determined as described in Materials and Methods and adjusted for multiple comparisons by the Bonferroni correction. Each peptide pool was analyzed in duplicate or triplicate wells. Only symbols of positive responders are specified in the legend. 26 -50 and Pol 226 -248 peptide pools, respectively, were not recognized (data not shown). However, despite intense efforts over extended time periods, these HIV-1 epitope-specific T cells did not expand in vitro. Of note, as mentioned above, T cells of neither ES15 nor ES29 reacted to a set of optimal 8-or 9-mer peptides, which were selected based on their reported restriction to HLA haplotypes present in these two individuals. In conclusion, the failure to map single HIV-1 epitopes in ES15 and to clone peptidereactive T cells in either ES15 or ES29 provides additional support that HIV-1-specific, IFN-␥-secreting T cells are unlikely to be a significant factor in helping these ES MSM resist HIV-1 infection.
Discussion
This investigation provides evidence that IFN-␥-secreting memory T cells recognizing HIV-1 epitopes are not consistently detectable in our ES individuals who continue to practice profoundly high risk activities for years. In fact, their T cell responses are not significantly different from those of a lower risk control group. Moreover, even when presenting HIV-1 epitopes through potent immunostimulatory DCs, most ES MSM tested exhibited minimal to absent numbers of HIV-1-specific, IFN-␥-secreting T cells. Nevertheless, two individuals clearly demonstrated high frequencies of T cells secreting IFN-␥ in response to several HIV-1 peptide pools presented by autologous DCs. Although these responses diminished in magnitude and breadth over time, it is possible that even low levels of HIV-1-specific, IFN-␥-secreting T cells may have contributed to rapid containment of HIV-1 following exposure in these individuals. It is also conceivable that the frequencies of HIV-1-specific T cells are higher at the sites of viral exposure, such as the rectal mucosa, than in peripheral blood. Kaul et al. (12) have suggested this possibility in their study examining the cervical mucosa of highly exposed CSW in Nairobi. Although we did not examine mucosal responses by IFN-␥ ELISPOT, in our previous unpublished studies we have examined mucosal CTL responses, and the frequencies were not greater than those of systemic CTL.
The scarcity of HIV-1-specific, IFN-␥-secreting T cells in our cohort must be reconciled with the findings of other studies that have implicated cellular immunity to be an important factor of resistance in multiply exposed, uninfected individuals (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) 48) . The first consideration is the potential for HIV-1 exposure in our ES, who were MSM, compared, for example, to the Nairobi CSW cohort, whose risk activities are heterosexual. The route of exposure differs in the two, with penile-vaginal intercourse, as practiced in the Nairobi cohort, having an ϳ10-fold lower chance of HIV-1 transmission than penile-anal intercourse (1), as practiced by our ES. However, due to the marked differences in HIV-1 seroincidence in the two geographic regions, the female CSW in Nairobi are likely to be exposed to greater numbers of HIV-1-infected partners in their clientele than our ES MSM in Seattle. We presume that the viral loads of the Nairobi CSW sexual partners are higher than those of our ES partners, in whom common antiretroviral therapy use may effectively decrease the likelihood of HIV-1 exposure. Of note, in our previous report we did compare the plasma HIV-1 RNA levels in our ES partners with those of a contemporary matched, HIV-1-infected population enrolled in clinical trials, and no significant differences were noted between these groups (10), indicating that the ES partners are not unusual in their virologic profiles. Despite these caveats, approximately half of our ES MSM and the ones chosen for further detailed analyses continued to regularly practice high risk MSM activities with the same HIV-1-infected or new partners up to 6 or more years of observation. At the same time, the seroconversion rate in this group was markedly lower than that in 100 ES MSM followed for the HIVNET Vaccine Preparedness Study (44) despite our risk criteria being significantly more stringent. Thus, although our ES MSM are probably exposed to fewer numbers of HIV-1-infected partners, and their partner viral loads may be lower than those of the African ES CSW cohort, the predominant route of exposure in our cohort may confer greater transmissibility. Moreover, the lower seroincidence rates in comparison with contemporary MSM suggests that our ES MSM may exhibit some degree of resistance that reduces the likelihood of transmission from their infected partners.
Our examination of the ES responses by the sensitive IFN-␥ ELISPOT methodologies was thorough, and if responses existed, they were likely to be revealed by these studies. It should be noted that the standard ELISPOT assay and the statistical interpretation of ELISPOT data have undergone rigorous evaluation (7, 36, 49) for validation purposes in phase II vaccine trials. We determine positive results with a stringent likelihood ratio statistic that maintains a consistent false positive rate of ␣ Յ 0.01 across all assays and also incorporates a Bonferroni correction for the testing of multiple peptide pools. Our method thus treats all ELISPOT results with identical stringency and tends to be more conservative for borderline responses than previously published criteria (10) . Low IFN-␥ SFC frequencies that would be considered positive using traditional cutoffs are thus more likely to be interpreted as negative by our statistical criteria. This in part may account for why our findings indicate that as a group the ES responses were no different from those of the control subjects.
We recognize that there remains the possibility that the effector response important in preventing overt infection in the ES may not be represented by the identification of IFN-␥-secreting T cells. In this case, the results of the present study stand in contrast with our own findings (10) of HIV-1-specific cytolysis in approximately one-third of ES MSM. This discrepancy can be explained largely by the different nature of the assays used and the effector cells tested. Although peptide presentation by DCs increased the ELISPOT sensitivity ϳ3-fold, the 16-h time frame of the assay precludes actual expansion of HIV-1-specific T cells. In contrast, cytolysis was measured 10 days after antigenic stimulation, which allows proliferation and differentiation of HIV-1-specific precursor T cells and thus increases the frequency of responding effector cells. The T cells from the ES have normal proliferative capacities, as they are derived from immunocompetent HIV-1-uninfected subjects (10, 50) . Thus, in ES, the ability to detect very low frequency responses may be greater in the CTL precursor analysis than the ex vivo ELISPOT analysis, in contrast to more recent studies comparing these assays in HIV-1-infected individuals (51) (52) (53) . Protocols measuring cytolytic activities may also be less prone to identifying weak cross-reactivities, because T cells have to pass two check points for specificity, one during initial stimulation and a second during lysis of target cells. Cytolysis assays may thus be more robust for identifying low frequency, but true HIV-1-specific, responses than ELISPOT assays. This can explain why we found a difference between the ES and the control cohort based on assessment of cytotoxicity in our earlier study, but detected no significant difference in the proportion of responders in the ES and the control cohort based on the DC-ELISPOT assay in our present study.
Difficulties in distinguishing true HIV-1 responses from crossreactivities may also explain some of the discrepancies found between studies conducted in different ES cohorts. There is compelling evidence that memory CTL triggered by one virus can be cross-reactive to Ags from another virus (54 -57) . The frequency of such cross-reactive responses is likely to increase with the number of exposures to virus-derived Ags, which may be reflected by the magnitude of overall immune activation. One can thus speculate that the higher levels of cellular activation found in people living in subSaharan Africa (58 -60) as well as in promiscuous ES individuals (61) are accompanied by broader and stronger cross-reactivities.
The possibility that certain cohorts exhibit higher levels of cross-reactivities underscores the importance of a well-matched control cohort to distinguish true HIV-1-specific from cross-reactive responses. To better distinguish cross-reactivities from responses stimulated by actual contact with HIV, we enrolled control subjects whose life style patterns were not that dissimilar from those of ES individuals: nine were MSM, and all 13 were sexually active. The controls were distinguished from ES mainly by the absence of reported contact with known HIV-1-infected partners. The reported HIV-1 seroincidence of 0.83/ 100 person-years in the Seattle metropolitan area (44) indicates a very small overall risk of HIV-1 exposure in our controls. When we compared the DC-ELIS-POT results between this control and the ES cohort, the proportion of subjects in each group who demonstrated HIV-1 cellular immunity was not significantly different. This suggests that for the most part we have observed true cross-reactive responses triggered by Ags other than derived from HIV-1. Alternatively, we may have recorded false positive responses due to the technical limitations of our assay. However, given the rigorous evaluation of the ELISPOT protocol, we think that this is unlikely.
The findings in this and our earlier study (10) lead us to believe that HIV-1-specific cellular immunity represented by IFN-␥-secreting T cells is either absent or extremely weak in the majority of ES MSM, and that resistance to infection conferred by IFN-␥-secreting T cells in our ES cohort is therefore relative at best. Of note, even in the few ES in whom we were able to detect such T cell responses, seroconversions did occur thereafter in two of them, which is consistent with other reports that some female CSW who have resisted for some time do go on to seroconvert (7, 8) . Moreover, in the two individuals, ES15 and ES29, who demonstrated relatively consistent responses recognizing several HIV-1 peptide pools and who have remained uninfected to date, we were unable to identify HIV-1 single epitope-specific memory T cell clones. Although this failure could have been due to technical problems, we believe that this is unlikely, since we made repeated attempts and have extensive experience with T cell cloning (6, 62, 63) , particularly from specimen sources containing extremely few HIV-1-specific T cells (62, 63) .
In conclusion, the low frequency of HIV-1-specific, IFN-␥-secreting T cells in the ES MSM cohort, the inability to demonstrate HIV-1-specific T cell clones in the few stronger responders, and the possibility that many of the low responses stem from cross-reactivities stimulated by viruses other than HIV argue against a prominent role of HIV-1-specific T cells that secrete IFN-␥ in preventing infection in our cohort. It is clear that the ES represent a unique population in whom mechanisms of HIV-1 protection can be elucidated (2, 4, 64, 65) , and that it is likely that multiple factors contribute to their relative resistance. Our findings emphasize the importance of considering the type and extent of risk activity as well as inclusion of appropriate controls in interpreting findings that may have a role in HIV-1 protection. Future studies comparing these methodologies in heterosexual ES from regions where the HIV-1 epidemic has hit hardest will be enlightening in understanding the role of IFN-␥-secreting T cells and other relevant antiviral mediators that confer protection.
